산후 출혈 치료 기기 시장 예측(2026-2032년)

The Postpartum Hemorrhage Treatment Devices Market is projected to grow by USD 1,423.20 million at a CAGR of 6.49% by 2032.

Postpartum Hemorrhage Treatment Devices: Executive Introduction

Postpartum hemorrhage treatment devices are central to obstetric emergency care because postpartum hemorrhage remains one of the leading causes of maternal mortality worldwide. These devices include uterine balloon tamponade systems, uterine vacuum-induced hemorrhage control devices, anti-shock garments, blood collection and quantification tools, compression devices, and adjunctive technologies used alongside uterotonics, tranexamic acid, resuscitation protocols, and surgical intervention when required. Demand is shaped by the urgent need for rapid bleeding control, standardized obstetric response pathways, and improved access to lifesaving maternal health technologies in hospitals, birth centers, and lower-resource delivery settings.

The clinical importance of postpartum hemorrhage treatment devices is reinforced by global maternal health priorities, quality-improvement initiatives, and guidance from organizations such as the World Health Organization, the International Federation of Gynecology and Obstetrics, and national obstetric bodies that emphasize early recognition, timely escalation, and coordinated multidisciplinary response. Device adoption is increasingly linked to practical performance factors such as speed of deployment, ease of training, compatibility with existing obstetric workflows, sterility assurance, cost-effectiveness, transportability, and suitability for both tertiary care and resource-constrained environments. As healthcare systems pursue safer childbirth outcomes, the postpartum hemorrhage treatment devices landscape is becoming more evidence-driven, protocol-led, and focused on equitable access to emergency obstetric care.

Transformative Shifts in the Postpartum Hemorrhage Device Landscape

The postpartum hemorrhage treatment devices landscape is undergoing a notable shift from reactive emergency intervention toward standardized, prevention-oriented, and protocol-integrated obstetric care. Labor and delivery units are increasingly adopting hemorrhage carts, quantitative blood loss assessment, simulation-based staff training, and stage-based response algorithms to reduce delays in diagnosis and treatment. This shift is strengthening the role of devices that can be rapidly deployed by trained clinicians and integrated into maternal early warning systems.

Another transformative change is the growing emphasis on minimally invasive and uterus-sparing hemorrhage control. Uterine balloon tamponade and vacuum-induced uterine compression technologies are gaining attention because they can provide mechanical bleeding control before escalation to invasive surgery, supporting the global clinical priority of reducing severe maternal morbidity where appropriate. In parallel, procurement decisions are being influenced by regulatory scrutiny, clinical evidence requirements, supply resilience, infection-prevention expectations, and usability across diverse care settings. Health systems are also focusing on interoperability between devices, electronic health records, blood bank workflows, and obstetric safety bundles to support faster decision-making and documentation. These changes are making postpartum hemorrhage treatment devices not only emergency products but also core components of maternal safety infrastructure.

Cumulative Impact of Artificial Intelligence on Hemorrhage Care

Artificial intelligence is beginning to influence postpartum hemorrhage care by improving risk stratification, workflow coordination, and real-time clinical decision support. AI-enabled models can analyze maternal history, laboratory results, vital signs, delivery characteristics, medication exposure, and prior obstetric complications to help identify patients at elevated risk for severe bleeding. When integrated with electronic health records and maternal early warning systems, these tools can support earlier preparedness, including activation of hemorrhage protocols, blood product readiness, and postpartum hemorrhage treatment device availability at the bedside.

The cumulative impact of artificial intelligence is also visible in operational and training applications. Predictive analytics can help optimize inventory of uterine tamponade devices, blood loss measurement tools, and emergency obstetric kits across facilities with variable delivery volumes. Computer vision and sensor-enabled systems may improve the accuracy of blood loss quantification, reducing reliance on visual estimation, which has been widely recognized in obstetric literature as inconsistent in clinical practice. AI-supported simulation and competency platforms can also help standardize provider training for postpartum hemorrhage response. However, adoption depends on careful clinical validation, bias mitigation, cybersecurity, transparent governance, data privacy safeguards, and alignment with obstetric guidelines so that AI complements rather than replaces clinician judgment.

Key Regional Insights Across Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is a critical region for postpartum hemorrhage treatment devices due to high birth volumes, expanding institutional delivery rates, and sustained maternal health investments across countries such as China, India, Japan, South Korea, and Australia. The region shows strong need for scalable, easy-to-use, and cost-sensitive hemorrhage control technologies that can function in both advanced hospitals and lower-resource facilities. National maternal health programs, emergency obstetric care training, and efforts to reduce preventable maternal deaths are supporting wider consideration of uterine tamponade systems, blood loss measurement tools, and structured hemorrhage response kits.

North America demonstrates advanced adoption of postpartum hemorrhage treatment devices through mature hospital infrastructure, obstetric safety bundles, quality reporting programs, and strong emphasis on standardized emergency response. The United States and Canada have placed significant focus on maternal morbidity reduction, simulation training, quantitative blood loss measurement, and multidisciplinary hemorrhage protocols. Latin America, led by countries such as Brazil and Mexico, reflects a mixed environment in which urban tertiary hospitals increasingly implement modern obstetric emergency devices while rural and underserved areas continue to require affordable, durable, and easy-to-train solutions that address access gaps in emergency obstetric care.

Europe is characterized by strong clinical governance, universal or broad-based healthcare access in many countries, and guideline-driven obstetric practice across nations including the United Kingdom, Germany, France, Italy, and Spain. Device adoption is shaped by evidence standards, procurement rules, medical device regulation, and patient safety initiatives focused on maternal morbidity reduction. The Middle East, particularly in GCC healthcare systems, is investing in advanced maternity infrastructure, specialist hospitals, and emergency care modernization, while broader access varies by country. Africa has the most urgent need for accessible postpartum hemorrhage treatment devices because postpartum hemorrhage remains a major contributor to maternal deaths, especially where blood products, referral systems, skilled birth attendance, and surgical capacity are limited. In this context, portable, low-cost, and training-friendly hemorrhage control devices are especially important.

Key Group Insights for ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries represent a highly diverse maternal health environment, with advanced urban hospitals operating alongside rural and island communities where timely emergency obstetric care can be difficult. This diversity supports demand for postpartum hemorrhage treatment devices that are compact, affordable, easy to sterilize or safely dispose of, and practical for midwife-led or district-level care settings. Regional priorities around reducing maternal mortality, strengthening referral networks, and improving skilled birth attendance continue to reinforce the need for standardized hemorrhage response tools.

The GCC group is distinguished by strong healthcare investment, modern maternity facilities, and growing emphasis on high-acuity obstetric care, making it receptive to advanced postpartum hemorrhage treatment devices, simulation training, and integrated emergency response systems. The European Union benefits from regulatory harmonization, cross-border clinical guidance, and structured procurement processes, which strengthen demand for devices supported by clinical evidence, safety compliance, and usability data. BRICS countries combine large birth populations, rapid health infrastructure development, and significant disparities in care access; this creates a dual need for advanced devices in tertiary hospitals and robust low-cost options for public health systems.

G7 countries generally have mature obstetric infrastructure, established blood bank access, and quality-improvement programs that favor adoption of validated hemorrhage control devices, quantitative blood loss tools, and protocol-integrated emergency kits. NATO countries overlap significantly with high-income health systems but also include varied healthcare capacities, making emergency preparedness, supply chain resilience, and standardized clinical training important considerations. Across these groups, the strongest opportunities are linked to devices that align with maternal safety programs, reduce time to intervention, support consistent provider competency, and remain reliable during obstetric emergencies.

Key Country Insights Across Major Postpartum Hemorrhage Device Markets

The United States is shaped by strong attention to maternal morbidity, obstetric safety bundles, and hospital-based quality initiatives that support the use of postpartum hemorrhage treatment devices in standardized emergency response. Canada similarly emphasizes evidence-based maternity care, regionalized perinatal services, and structured clinical pathways. Mexico and Brazil face the dual challenge of improving advanced obstetric services in major urban centers while ensuring reliable access to emergency hemorrhage control in public hospitals and underserved regions, where affordability, training, and referral readiness remain critical.

In Europe, the United Kingdom has advanced national attention on maternity safety, clinical audits, and rapid escalation protocols, while Germany and France reflect strong hospital infrastructure and guideline-led obstetric management. Italy and Spain continue to strengthen maternal safety practices through regional health systems and standardized clinical training, whereas Russia's large geography creates a need for adaptable devices and resilient distribution across varied care settings. Across these countries, procurement favors technologies supported by clinical usability, safety documentation, regulatory compliance, and compatibility with established obstetric protocols.

China and India are highly important countries because of large delivery volumes, ongoing maternal health reforms, and the need to expand emergency obstetric capacity across multiple levels of care. China's hospital modernization and India's public health focus on institutional delivery and maternal mortality reduction support interest in scalable postpartum hemorrhage treatment devices. Japan, South Korea, and Australia have advanced healthcare systems, strong clinical governance, and high expectations for device quality, training, and safety. These countries are likely to prioritize solutions that enhance rapid response, reduce severe maternal morbidity, and integrate smoothly with multidisciplinary maternity care.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize device designs that support rapid deployment, intuitive use, and effectiveness across both high-resource and resource-constrained delivery environments. Products should be aligned with recognized postpartum hemorrhage protocols, quantitative blood loss practices, maternal early warning systems, and simulation-based training programs. Usability testing with obstetricians, midwives, nurses, anesthesiology teams, emergency care providers, and biomedical teams can improve adoption and reduce workflow friction during high-stress hemorrhage events.

Manufacturers and healthcare stakeholders should invest in clinical evidence generation, post-market surveillance, human factors validation, and training materials that demonstrate safety, practical performance, and provider competency. Regional strategies should reflect local maternal health priorities, procurement requirements, reimbursement pathways, infrastructure realities, and regulatory expectations. In lower-resource settings, affordability, portability, simplified instructions, minimal maintenance, and reliable supply chains are essential. In advanced systems, integration with digital documentation, blood bank workflows, and AI-enabled risk tools can enhance value. Partnerships with public health programs, professional societies, and training institutions can further support responsible adoption while improving readiness for obstetric emergencies.

Research Methodology

This executive summary is developed through a structured secondary research approach focused on verified public health, clinical, regulatory, and healthcare delivery sources. The methodology considers evidence from global maternal health guidance, obstetric emergency care recommendations, peer-reviewed clinical literature, regulatory frameworks, national health initiatives, and publicly available information on maternal safety programs. Emphasis is placed on postpartum hemorrhage treatment devices used for mechanical bleeding control, blood loss assessment, emergency stabilization, and protocol-based obstetric response.

The analysis applies qualitative triangulation to identify consistent patterns across regions, country health systems, device categories, and clinical adoption drivers. It excludes market estimation, market sizing, market share, and forecasting, and instead focuses on evidence-backed trends, implementation barriers, care delivery needs, and strategic implications. Regional, group, and country insights are assessed through the lens of maternal mortality burden, health system maturity, institutional delivery access, emergency obstetric capacity, training infrastructure, medical device regulation, and procurement conditions. This approach supports a balanced, SEO-optimized assessment of the postpartum hemorrhage treatment devices landscape without relying on speculative commercial projections.

Conclusion

Postpartum hemorrhage treatment devices are becoming indispensable components of modern maternal safety strategies. Their role extends beyond emergency intervention to include preparedness, workflow standardization, training, blood loss recognition, and coordinated escalation of care. The strongest industry momentum is tied to devices that help clinicians act quickly, preserve fertility when possible, reduce delays in treatment, and function reliably across diverse care environments.

Global adoption will continue to be shaped by maternal health priorities, clinical evidence, regulatory expectations, affordability, and healthcare system readiness. Artificial intelligence, digital documentation, quantitative blood loss tools, and protocol-integrated devices are creating a more connected approach to obstetric hemorrhage management. For industry leaders, the most important strategic direction is clear: develop clinically validated, accessible, easy-to-use, and training-supported postpartum hemorrhage treatment devices that improve emergency readiness and contribute to safer childbirth outcomes worldwide.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Postpartum Hemorrhage Treatment Devices Market, by Device Type

• 7.1. Introduction
• 7.2. Elastic Bandage Systems
  • 7.2.1. Abdominal Compression Wrapping
  • 7.2.2. Pelvic Binders
• 7.3. Electrosurgical Devices
  • 7.3.1. Bipolar Devices
  • 7.3.2. Monopolar Devices
• 7.4. Hemostatic Agents
  • 7.4.1. Collagen Based Agents
  • 7.4.2. Gelatin Based Agents
  • 7.4.3. Powders
  • 7.4.4. Sponges
• 7.5. Suturing Systems
  • 7.5.1. Prefabricated Suturing Devices
  • 7.5.2. Standard Suturing Kits
• 7.6. Uterine Balloon Tamponade
  • 7.6.1. Commercial Tamponade Balloon
  • 7.6.2. Condom Tamponade

8. Postpartum Hemorrhage Treatment Devices Market, by Condition Type

• 8.1. Introduction
• 8.2. Primary Postpartum Hemorrhage
• 8.3. Secondary Postpartum Hemorrhage

9. Postpartum Hemorrhage Treatment Devices Market, by Technology

• 9.1. Introduction
• 9.2. Mechanical Hemorrhage Control Devices
• 9.3. Pharmacologic Delivery Devices
• 9.4. Smart & AI-enabled Systems

10. Postpartum Hemorrhage Treatment Devices Market, by Application

• 10.1. Introduction
• 10.2. Uterine Atony Management
• 10.3. Trauma-related Hemorrhage
• 10.4. Placental Complication Management
• 10.5. Coagulation Disorder Management
• 10.6. Emergency Stabilization
• 10.7. Preventive Use During High-risk Deliveries

11. Postpartum Hemorrhage Treatment Devices Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Postpartum Hemorrhage Treatment Devices Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Postpartum Hemorrhage Treatment Devices Market, by Country

• 13.1. United States
• 13.2. Canada
• 13.3. Mexico
• 13.4. Brazil
• 13.5. United Kingdom
• 13.6. Germany
• 13.7. France
• 13.8. Russia
• 13.9. Italy
• 13.10. Spain
• 13.11. China
• 13.12. India
• 13.13. Japan
• 13.14. Australia
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. 3rd Stone Design, Inc.
• 15.2. Alydia Health
• 15.3. Becton, Dickinson and Company
• 15.4. CELOX Medical
• 15.5. Clinical Innovations, LLC
• 15.6. Cook Medical, Inc.
• 15.7. CooperSurgical, Inc.
• 15.8. Dr. Arabin GmbH & Co. KG
• 15.9. Go Medical Industries Pty Ltd.
• 15.10. HLL Lifecare Limited
• 15.11. Laborie Medical Technologies, Inc.
• 15.12. Laerdal Global Health
• 15.13. Maternova, Inc.
• 15.14. MedGyn Products, Inc.
• 15.15. Organon & Co.
• 15.16. Panpac Medical Corporation
• 15.17. PATH
• 15.18. Pathfinder Health Innovations
• 15.19. Pregna International Ltd.
• 15.20. Sinapi Biomedical
• 15.21. Sinolinks Medical Innovation Inc.
• 15.22. Teleflex Incorporated
• 15.23. Utah Medical Products, Inc.